🇪🇺 Bimatoprost (SR) in European Union

Bimatoprost (SR) (Bimatoprost (SR)) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005916
  • Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
  • Local brand name: Durysta
  • Indication: Indicated for the reduction of intraocular pressure (IOP) in adults with open angle glaucoma (OAG) or ocular hypertension (OHT) who are unsuitable for topical IOP-lowering medications.
  • Status: withdrawn

Read official source →

Bimatoprost (SR) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Ophthalmology approved in European Union

Frequently asked questions

Is Bimatoprost (SR) approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Bimatoprost (SR) in European Union?

AbbVie Deutschland GmbH & Co. KG holds the EU marketing authorisation.